Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRAD MATTHEW TAICHER

Allopathic & Osteopathic Physicians Anesthesiology

NPI
1346445400
CMS profile
999794
Location
DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,564.90

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,107.09 4
Food and Beverage $457.81 9

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Pacira Pharmaceuticals Incorporated $1,564.90 13

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRAD MATTHEW TAICHER

NPI 1346445400 · CMS profile ID 999794

Allopathic & Osteopathic Physicians / Anesthesiology

DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346445400?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRAD MATTHEW TAICHER, NPI 1346445400, CMS profile ID 999794. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346445400?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). BRAD MATTHEW TAICHER, NPI 1346445400, CMS profile ID 999794. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346445400?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
BRAD MATTHEW TAICHER, NPI 1346445400, CMS profile ID 999794, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1346445400?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $1,564.90 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Pacira Pharmaceuticals Incorporated $23.1102/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692948307 CMS
Pacira Pharmaceuticals Incorporated $54.0002/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692948309 CMS
Pacira Pharmaceuticals Incorporated $443.7001/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692948293 CMS
Pacira Pharmaceuticals Incorporated $55.2701/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692948295 CMS
Pacira Pharmaceuticals Incorporated $16.5901/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692948297 CMS
Pacira Pharmaceuticals Incorporated $31.8401/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692948299 CMS
Pacira Pharmaceuticals Incorporated $70.8901/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692948301 CMS
Pacira Pharmaceuticals Incorporated $16.8701/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692948303 CMS
Pacira Pharmaceuticals Incorporated $29.1901/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692948305 CMS
Pacira Pharmaceuticals Incorporated $438.7901/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692948285 CMS
Pacira Pharmaceuticals Incorporated $170.6001/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692948287 CMS
Pacira Pharmaceuticals Incorporated $165.8501/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692948289 CMS
Pacira Pharmaceuticals Incorporated $48.2001/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692948291 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,564.90 13
PY2020 $1,800.00 1
PY2025 $64.93 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $4,358.00 2
PY2022 Principal investigator $101,388.75 26
PY2021 Principal investigator $79,582.83 5
PY2020 Principal investigator $5,712.16 2
PY2019 Principal investigator $171,112.71 77

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

77 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $5,488.33 11/22/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691472267
Principal investigator 1 Pacira Pharmaceuticals Incorporated $29,074.41 11/06/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS. No dispute reported 06/30/2026 693062161
Principal investigator 1 Merck Sharp & Dohme Corporation $9,808.00 10/25/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691449043
Principal investigator 1 Merck Sharp & Dohme Corporation $1.04 10/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691467303
Principal investigator 1 Merck Sharp & Dohme Corporation $1.84 10/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691467643
Principal investigator 1 Merck Sharp & Dohme Corporation $79.20 10/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691467647
Principal investigator 1 Merck Sharp & Dohme Corporation $1.26 10/03/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691361669
Principal investigator 1 Merck Sharp & Dohme Corporation $1.26 10/03/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691465899
Principal investigator 1 Merck Sharp & Dohme Corporation $22,878.84 09/18/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691384409
Principal investigator 1 Merck Sharp & Dohme Corporation $189.72 09/12/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691385057
Principal investigator 1 Merck Sharp & Dohme Corporation $494.68 09/12/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691385841
Principal investigator 1 Merck Sharp & Dohme Corporation $37,633.00 09/11/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691405835
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 09/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691386333
Principal investigator 1 Merck Sharp & Dohme Corporation $1.56 09/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691405775
Principal investigator 1 Merck Sharp & Dohme Corporation $39.60 09/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691406639
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 09/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691408465
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 09/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691408469
Principal investigator 1 Merck Sharp & Dohme Corporation $2.76 09/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691451943
Principal investigator 1 Merck Sharp & Dohme Corporation $17.40 08/14/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691327367
Principal investigator 1 Merck Sharp & Dohme Corporation $234.31 08/14/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691327371
Principal investigator 1 Merck Sharp & Dohme Corporation $6.99 08/01/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691327379
Principal investigator 1 Merck Sharp & Dohme Corporation $195.57 07/25/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691385063
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691360929
Principal investigator 1 Merck Sharp & Dohme Corporation $15.75 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691360931
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691360937
Principal investigator 1 Merck Sharp & Dohme Corporation $23.28 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691360939
Principal investigator 1 Merck Sharp & Dohme Corporation $3.40 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691360943
Principal investigator 1 Merck Sharp & Dohme Corporation $1.90 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691361645
Principal investigator 1 Merck Sharp & Dohme Corporation $0.11 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691361693
Principal investigator 1 Merck Sharp & Dohme Corporation $0.12 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691361697
Principal investigator 1 Merck Sharp & Dohme Corporation $0.12 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691361701
Principal investigator 1 Merck Sharp & Dohme Corporation $0.23 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691361707
Principal investigator 1 Merck Sharp & Dohme Corporation $0.26 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691361711
Principal investigator 1 Merck Sharp & Dohme Corporation $1.24 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691361715
Principal investigator 1 Merck Sharp & Dohme Corporation $3.80 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691361985
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691361987
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691361991
Principal investigator 1 Merck Sharp & Dohme Corporation $39.60 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691361993
Principal investigator 1 Merck Sharp & Dohme Corporation $4.14 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691362019
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691362025
Principal investigator 1 Merck Sharp & Dohme Corporation $5.28 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691362534
Principal investigator 1 Merck Sharp & Dohme Corporation $9.90 07/10/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691362539
Principal investigator 1 Merck Sharp & Dohme Corporation $9,808.00 06/21/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691354369
Principal investigator 1 Merck Sharp & Dohme Corporation $144.60 06/19/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691371615
Principal investigator 1 Pacira Pharmaceuticals Incorporated $14,403.50 06/18/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS. No dispute reported 06/30/2026 693062083
Principal investigator 1 Pacira Pharmaceuticals Incorporated $1,670.90 05/29/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS. No dispute reported 06/30/2026 708146905
Principal investigator 1 Merck Sharp & Dohme Corporation $23.07 05/13/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691347433
Principal investigator 1 Merck Sharp & Dohme Corporation $49.50 05/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691361353
Principal investigator 1 Merck Sharp & Dohme Corporation $1.82 05/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691361718
Principal investigator 1 Merck Sharp & Dohme Corporation $4.37 05/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691362039
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 05/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691362293
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 05/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691373179
Principal investigator 1 Merck Sharp & Dohme Corporation $204.25 04/26/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691371623
Principal investigator 1 Merck Sharp & Dohme Corporation $35.85 04/16/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691371627
Principal investigator 1 Merck Sharp & Dohme Corporation $17,024.43 04/15/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691313445
Principal investigator 1 Merck Sharp & Dohme Corporation $3.08 04/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691360805
Principal investigator 1 Merck Sharp & Dohme Corporation $118.80 04/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691360945
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 04/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691361029
Principal investigator 1 Merck Sharp & Dohme Corporation $6.84 04/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691361093
Principal investigator 1 Merck Sharp & Dohme Corporation $3.80 04/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691361229
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 04/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691361281
Principal investigator 1 Merck Sharp & Dohme Corporation $12.24 04/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691361877
Principal investigator 1 Merck Sharp & Dohme Corporation $4.14 04/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691362035
Principal investigator 1 Merck Sharp & Dohme Corporation $19.80 04/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691362441
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 04/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691362467
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 04/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691362474
Principal investigator 1 Merck Sharp & Dohme Corporation $2.08 04/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691363001
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 04/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691363145
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 04/08/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691363147
Principal investigator 1 Merck Sharp & Dohme Corporation $9.15 03/07/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691370431
Principal investigator 1 Merck Sharp & Dohme Corporation $7,309.00 02/27/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691313553
Principal investigator 1 Merck Sharp & Dohme Corporation $9.39 02/26/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691370435
Principal investigator 1 Merck Sharp & Dohme Corporation $465.26 02/21/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616)for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691540063
Principal investigator 1 Merck Sharp & Dohme Corporation $137.58 02/14/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616)for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691286061
Principal investigator 1 Merck Sharp & Dohme Corporation $494.68 02/14/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616)for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691286115
Principal investigator 1 Merck Sharp & Dohme Corporation $758.88 02/14/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616)for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691540061
Principal investigator 1 Merck Sharp & Dohme Corporation $11,651.42 02/06/2019 Covered Recipient Teaching Hospital
DUKE UNIVERSITY HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691384405